Dexmedetomidine for paroxysmal sympathetic hyperactivity in a patient with traumatic brain injury: a case report in the intensive care unit by Lasithiotaki, Ismini et al.
Dexmedetomidine for Paroxysmal 
Sympathetic Hyperactivity in a Patient 
with Traumatic Brain Injury: A Case 
Report in the Intensive Care Unit
Ismini Lasithiotaki,1 Aikaterini Megalou,1 Stefanos Korfias,2  
Stamatis Banos,2 Charikleia S. Vrettou1
A b s t r A c t
In this case report we describe the course of a patient with severe traumatic brain 
injury who, upon withdrawal of sedation, presented the characteristic clinical signs of 
paroxysmal sympathetic hyperactivity and responded to the combination of dexme-
detomidine infusion and oral metoprolol. We present the diagnostic and therapeu-
tic rationale that guided our decisions and summarize the current knowledge on the 
topic.
I n t r o d u c t I o n
Paroxysmal sympathetic hyperactivity presents a diagnostic and therapeutic chal-
lenge in intensive care medicine. If undiagnosed, it can delay successful weaning from 
sedation and mechanical ventilation and become a real threat to patients’ life and 
neurological outcome due to hyperthermia or hemodynamic derangement. To our 
knowledge there are four cases in the medical literature describing the use of dexme-
detomidine for paroxysmal sympathetic hyperactivity and only one of them discusses 
a patient with head trauma.
c A s e  p r e s e n t A t I o n
A 22 year old male was admitted in the intensive care unit (ICU) following severe 
traumatic brain injury (TBI), due to a motorcycle road traffic accident, with Glasgow 
coma scale score (GCS) 4 (eye opening=1, motor=2, verbal=1). Computerized to-
mography (CT) of the brain is shown in Figure 1. Neurosurgical consultation advised 
conservative management. The patient’s course was complicated by intracranial pres-
sure (ICP) spikes as high as 45 mmHg and an ICP protocol was applied, including 
hyperosmolar therapy and maintenance of normothermia. A barbiturate infusion 
was added on day eight post admission for five days and was discontinued following 
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FIgure 1. Computerized tomography of the brain on admis-
sion shows cerebral contusions, traumatic subarachnoid hem-
orrhage, pneumocephalus and significant brain edema (loss of 
grey-white matter differentiation, reduced size of ventricles and 
subarachnoid space). There are also fractures of the sphenoid 
sinus, of the left orbit and temporal bone.
FIgure 2. Daily dosage requirements of dexmedetomidine and 
metoprolol. Filled triangle: total daily dose of dexmedetomine. 
Filled square: total daily dose of metoprolol. Hourly infusion 
range for dexmedetomidine was 0.005-0.025 μg/Kg/min. Dose 
reductions were attempted on day 3 and daily afterwards.
adequate ICP control. Paracetamol and intravenous antibiot-
ics (meropenem and colistin) were also administered to treat 
febrile episodes but an infection source was not identified.
Two days after the discontinuation of barbiturates the 
patient opened his eyes spontaneously. He was febrile 38.6 oC 
on paracetamol 3 g/day, tachycardic (120-140 bpm), tachypneic 
(35-38 breaths/min, arterial CO2=30-32 mmHg) and hyper-
tensive (systolic blood pressure 150-180 mmHg). Diaphoresis, 
dilated pupils reacting briskly to light and extensor posturing 
were also noticed. Posturing, tachycardia and hypertension 
were elicited with tactile stimuli and suction of the endotra-
cheal tube. Repeated brain CT scan showed improvement of 
edema and the presence of sphenoid sinus fluid collections. 
His chest x-ray was normal. Inflammatory markers were as fol-
lows: white cell count (WCC) = 11 x 103/μL 80% neutrophils, 
C-reactive protein (CRP) = 9.01 mg/dL and procalcitonin 
(PCT) = 0.07 ng/mL. A lumbar puncture and Cerebrospinal 
fluid (CSF) analysis showed 10 cells/mm3 (7 lymphocytes, 3 
neutrophils), 450 red blood cells/mm3 (80% “recent”), glucose 
60 mg/dL (serum glucose 100 mg/dL) and total protein 62 mg/
dL. The patient was sedated with propofol and remifentanyl. 
Tracheostomy and endoscopic drainage of the sphenoid sinus 
were performed on day 17. Pseudomonas aeruginosa and Aci-
netobacter baumanii sensitive to meropenem and colistin were 
cultured from bronchial secretions and sphenoid sinus samples 
respectively. Thyroid stimulating hormone was normal.
Sedation was discontinued after the tracheostomy and the 
patient was successfully weaned from mechanical ventilation. 
Episodes (two to three times a day) of hypertension, tachypnea, 
tachycardia, pupil dilation and posturing emerged on minimal 
stimulation and were not alleviated with morphine 1mg/h and 
esmolol 50 μg/Kg/min. Diazepam 10 mg iv was also ineffective. 
Dexmedetomidine infusion was initiated at this phase at 0.024 
μg/Kg/min. Morphine, esmolol and diazepam were gradually 
withdrawn and an electroencephalogram was performed that 
showed no evidence of epilepsy.
Oral metoprolol 25 mg twice daily was added in an attempt 
to wean off dexmedetomidine within 72 hours. This was not 
successful due to symptom relapse and dexmedetomidine 
was continued and titrated to symptom control (Fig. 2). As 
metoprolol dose was gradually increased and the episodes of 
posturing, hypertension tachycardia and diaphoresis became 
sparser (<2 per day) dexmedetomidine infusion rate was re-
duced and was finally discontinued 12 days after its initiation. 
The patient was discharged from ICU afebrile on metoprolol 
75 mg twice daily with improved neurological status. After 
closure of his tracheostomy he was able to go home with a 
physiotherapy plan, fully oriented and obeying commands.
d I s c u s s I o n
Episodic agitation, diaphoresis, hyperthermia, tachycar-
dia, tachypnea and rigid decerebrate posturing after severe 
brain injury were first described by Strich in 1956 using the 
term “brainstem attacks”.1 The term Paroxysmal sympathetic 
hyperactivity (PSH) has been suggested as a clinically more 
accurate term for the condition.2 Diagnostic criteria proposed 
for this entity are: i) history of severe brain injury (Rancho Los 
Amigos level IV), ii) core temperature of at least 38.5°C, iii) 
pulse rate of at least 130 bpm, iv) respiratory rate of at least 
30 breaths/min, v) agitation, vi) diaphoresis, and vii) dystonia 
(i.e. rigidity or decerebrate posturing).3 The frequency and 
duration of the symptoms must be at least 1 cycle per day for 
3 days. Aortic trauma and medical conditions shown in Table 
1 must be ruled out.4 The pathophysiology of PSH remains un-
clear but current literature supports dysfunction of autonomic 
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centers in the diencephalon (thalamus or hypothalamus) or 
their connections to cortical, subcortical, and brainstem loci 
that mediate autonomic function.5-7
Our patient fulfilled the criteria for PSH. CSF examination 
was consistent with traumatic subarachnoid hemorrhage and 
did not support a diagnosis of meningitis. Sphenoiditis related 
to craniofacial fractures could be the cause of hyperventilation, 
pyrexia and tachycardia, but cannot explain the hypertension, 
the decerebrate posturing and the episodic presentation of 
symptoms. Opiate withdrawal, pain and agitation would likely 
respond to intravenous morphine. We therefore attribute the 
clinical signs to PSH possibly overlapping with infection.
Adequate control of PSH is important in order to avoid 
complications such as intracranial or severe arterial hyper-
tension, cardiac arrhythmias, dehydration and secondary 
brain injury caused by hyperthermia. Patients should receive 
sufficient hydration and hyperthermia must be treated ag-
gressively. Pain, bladder distention and body turning that can 
trigger the symptoms should be avoided.8 Table 2 presents the 
pharmacologic treatment options for PSH and for conditions 
that may be ovarlapping with or mimicking it.9-12 Our patient 
did not respond to morphine, β blocker and diazepam. We 
decided to try dexmedetomidine in combination with a β 
blocker at that stage. Dexmedetomidine is a selective α2 re-
ceptor agonist whose sedative effects are mediated through 
decreased firing of locus ceruleus in the brainstem.13-15 The 
α2 agonists’ pattern of sedation is quite different from that 
of other sedative agents: patients can be aroused, their neu-
Table 1. Key findings for differential diagnosis between Paroxysmal Sympathetic Hyperactivity syndrome and other 
conditions
Diagnosis Findings that may differentiate from PSH
Malignant hyperthermia History of anesthetic agent exposure, rhabdomyolysis (high CK) and myoglobinuria are present
Neuroleptic malignant 
syndrome (NMS)
History of neuroleptic medication use (1-4 weeks prior to presentation), blood pressure may be low, 
rhabdomyolysis (CK) and myoglobinuria are present
Lethal catatonia Subacute onset of insomnia, anorexia, delusions. Occurring in patients without prior exposure to 
predisposing medications (unlike NMS). Psychomotor retardation usually present. CK may be high
Increased ICP Heart and breathing rate may be low and irregular, ICP monitoring and/or brain imaging are usu-
ally diagnostic
Central fever Fever may be the only sign present. Blood pressure heart rate and pupil size are usually unaffected. 
Rigidity is usually absent
Infections/Sepsis Hypertension, diaphoresis, rigidity and pupillary dilation are usually absent. WBC, CRP, lactic acid 
elevated. Positive cultures. Imaging suggestive
Systemic Inflammatory 
Response Syndrome (SIRS)
Hypertension is usually absent. Presentation is not episodic. Rigidity/decerebrate posturing are 
absent
Non convulsive epilepsy EEG findings can be diagnostic. Elevated post-ictal prolactin is suggestive
Agitation The patient exhibits purposeful movement, pyrexia is absent
Narcotic withdrawal Dystonia, extension posturing and pyrexia are absent
Autonomic dysreflexia History of spinal cord lesion, pupil dilation is absent
Pulmonary embolism Oxygenation defect, CTPA may be diagnostic. Rigidity/decerebrate posturing are absent
Thyroid storm Exophthalmos, cardiac arrhythmias and GI symptoms. Deregulation of thyroid hormones is present
Serotonin syndrome History of serotonergic medication use. Diarrhea, hypomania/confusion, ataxia usually present
Delirium tremens History of alcohol abuse associated with alcohol withdrawal. Palpitations, fatigue, nausea and 
vomiting, changes in mental status and hallucinations
PSH: paroxysmal autonomic hyperactivity, ICP: IntraCranial Pressure, WBC: white blood cells, CRP:C-reactive protein, EEG: electroencephalograph, 
CK: Creatinine Kinase, CTPA: computed tomography pulmonary angiogram, GI: gastrointestinal, SSRI: selective serotonin reuptake inhibitor
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rological performance is usually well preserved16,17 and the 
respiratory system is not depressed.18,19 Main adverse effects 
are hypotension and bradycardia.
We preferred dexmedetomidine to clonidine, an older α2 
receptor agonist, for our patient because it binds α2 receptors 
eight times more avidly than clonidine and is shorter acting 
making dose titration easier.20 Figure 2 shows the doses of the 
two medications used. In the cases where dexmedetomidine 
use in PSH has been described, continuous infusions were 
administered for up to 72 hours.21,22 Our patient required a 
longer infusion for symptom control following the gradual 
titration of metoprolol to 75 mg twice a day. 
In conclusion, our case shows that dexmedetomidine can 
be used in “difficult to wean” post TBI patients that present 
symptoms of PSH. Since PSH shares common features with 
other conditions commonly encountered in the ICU the pos-
sibility of another diagnosis mimicking or overlapping with 
PSH must be taken into account when making therapeutic 
choices. Evidence on the effectiveness of treatment comes only 
from case reports and case series and should be the target of 
research in intensive care and neurorehabilitation.
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